InnaVirVax is developing at the clinical stage an innovating therapy for HIV infection that will act in synergy with antiretrovirals.
InnaVirVax, incorporated in 2008, is a French biopharmaceutical company. Its most advanced project is an innovative therapy for HIV infection that has completed a Phase I/IIa clinical trial and been found to be safe and well tolerated. This therapy would act in synergy with antiretrovirals, reducing the morbity and mortality of this disease. At peak sales, it is expected yearly worth is expected to be more than €1 billion.